Francoise Farace
Overview
Explore the profile of Francoise Farace including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mezquita L, Oulhen M, Aberlenc A, Deloger M, Aldea M, Honore A, et al.
Br J Cancer
. 2024 Jan;
130(4):682-693.
PMID: 38177660
Background: Resistance mechanisms to combination therapy with dabrafenib plus trametinib remain poorly understood in patients with BRAF-mutant advanced non-small-cell lung cancer (NSCLC). We examined resistance to BRAF inhibition by single...
2.
Tayoun T, Faugeroux V, Oulhen M, Deas O, Michels J, Brulle-Soumare L, et al.
JCI Insight
. 2022 May;
7(11).
PMID: 35511434
DNA damage and genomic instability contribute to non-small cell lung cancer (NSCLC) etiology and progression. However, their therapeutic exploitation is disappointing. CTC-derived explants (CDX) offer systems for mechanistic investigation of...
3.
Oulhen M, Pawlikowska P, Tayoun T, Garonzi M, Buson G, Forcato C, et al.
NPJ Precis Oncol
. 2021 Jul;
5(1):67.
PMID: 34272470
Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic Lymphoma Kinase (ALK)-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are relevant tools to identify additional...
4.
Foy V, Lindsay C, Carmel A, Fernandez-Gutierrez F, Krebs M, Priest L, et al.
Transl Lung Cancer Res
. 2021 May;
10(4):1653-1665.
PMID: 34012782
Background: Circulating tumour cell (CTC) number is an independent prognostic factor in patients with small cell lung cancer (SCLC) but there is no consensus on the CTC threshold for prognostic...
5.
Tayoun T, Oulhen M, Aberlenc A, Farace F, Pawlikowska P
Cells
. 2021 Feb;
10(2).
PMID: 33562741
Circulating tumor cells (CTCs) provide an accessible tool for investigating tumor heterogeneity and cell populations with metastatic potential. Although an in-depth molecular investigation is limited by the extremely low CTC...
6.
Neves R, Ammerlaan W, Andree K, Bender S, Cayrefourcq L, Driemel C, et al.
Clin Chem
. 2021 Jan;
67(4):631-641.
PMID: 33491069
Background: Multiple technologies are available for detection of circulating tumor cells (CTCs), but standards to evaluate their technical performance are still lacking. This limits the applicability of CTC analysis in...
7.
Jannier S, Kemmel V, Sebastia Sancho C, Chammas A, Sabo A, Pencreach E, et al.
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33092063
Hypoxic environment is a prognostic factor linked in pediatric cancers to a worse outcome, favoring tumor progression and resistance to treatments. The activation of mechanistic Target Of Rapamycin (mTor)/hypoxia inducible...
8.
Faugeroux V, Pailler E, Oulhen M, Deas O, Brulle-Soumare L, Hervieu C, et al.
Nat Commun
. 2020 Apr;
11(1):1884.
PMID: 32313004
Transformation of castration-resistant prostate cancer (CRPC) into an aggressive neuroendocrine disease (CRPC-NE) represents a major clinical challenge and experimental models are lacking. A CTC-derived eXplant (CDX) and a CDX-derived cell...
9.
Tayoun T, Faugeroux V, Oulhen M, Aberlenc A, Pawlikowska P, Farace F
Cells
. 2019 Sep;
8(10).
PMID: 31557946
Metastasis is the main cause of cancer-related death owing to the blood-borne dissemination of circulating tumor cells (CTCs) early in the process. A rare fraction of CTCs harboring a stem...
10.
Pailler E, Faugeroux V, Oulhen M, Mezquita L, Laporte M, Honore A, et al.
Clin Cancer Res
. 2019 Aug;
25(22):6671-6682.
PMID: 31439588
Purpose: Patients with anaplastic lymphoma kinase ()-rearranged non-small-cell lung cancer (NSCLC) inevitably develop resistance to ALK inhibitors. New diagnostic strategies are needed to assess resistance mechanisms and provide patients with...